|
BNC210 (also known as IW-4123 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor,〔http://www.bionomics.com.au/upload/investors/asx-announcements/4736/ASX695%20%20BNC210%20Phase%201b%20initiation.pdf〕 by Bionomics Limited. It demonstrates clinically significant anxiety reduction in both animal models and in Phase I trials. It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models. Phase I trials have shown no serious side effects. Bionomics previously licensed it to Ironwood Pharmaceuticals, where it was known as IW-2143. IW-2143 was undergoing phase I clinical trials in the United States,〔http://investor.ironwoodpharma.com/releasedetail.cfm?ReleaseID=733540〕 but in November 2014, was released back to Bionics in a mutual agreement.〔http://www.biotechdaily.com.au/media/backissues/2014/11%20Nov/BD%20Biotech%20Daily%20Nov%2011.pdf〕 Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done. As of April 2015, BNC210 is in phase II clinical trials. ==See also== * 5-Hydroxyindoleacetic acid * Kynurenic acid 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「BNC210」の詳細全文を読む スポンサード リンク
|